MXPA06011569A - Microfluidized oil-in-water emulsions and vaccine compositions - Google Patents
Microfluidized oil-in-water emulsions and vaccine compositionsInfo
- Publication number
- MXPA06011569A MXPA06011569A MXPA/A/2006/011569A MXPA06011569A MXPA06011569A MX PA06011569 A MXPA06011569 A MX PA06011569A MX PA06011569 A MXPA06011569 A MX PA06011569A MX PA06011569 A MXPA06011569 A MX PA06011569A
- Authority
- MX
- Mexico
- Prior art keywords
- oil
- vaccine
- formulation
- antigen
- emulsion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 235
- 229960005486 vaccines Drugs 0.000 title claims abstract description 192
- 239000000839 emulsion Substances 0.000 title abstract description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract description 66
- 239000000427 antigen Substances 0.000 claims abstract description 127
- 108091007172 antigens Proteins 0.000 claims abstract description 127
- 102000038129 antigens Human genes 0.000 claims abstract description 127
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 52
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 37
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 36
- 235000012000 cholesterol Nutrition 0.000 claims description 26
- 229940107161 Cholesterol Drugs 0.000 claims description 25
- 239000007764 o/w emulsion Substances 0.000 claims description 23
- -1 saponin glycoside Chemical class 0.000 claims description 19
- 239000000693 micelle Substances 0.000 claims description 18
- 230000003612 virological Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000001580 bacterial Effects 0.000 claims description 8
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 7
- 235000019892 Stellar Nutrition 0.000 claims description 5
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims description 2
- PPBOKXIGFIBOGK-BDTUAEFFSA-N BVDV Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 claims 1
- 150000003648 triterpenes Chemical class 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 abstract description 72
- 230000000240 adjuvant Effects 0.000 abstract description 72
- 230000002708 enhancing Effects 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 description 106
- 239000003921 oil Substances 0.000 description 88
- 235000019198 oils Nutrition 0.000 description 88
- 238000002360 preparation method Methods 0.000 description 72
- 241000700605 Viruses Species 0.000 description 54
- 235000017709 saponins Nutrition 0.000 description 41
- 239000000243 solution Substances 0.000 description 39
- 150000007949 saponins Chemical class 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 35
- 239000004094 surface-active agent Substances 0.000 description 26
- 239000005662 Paraffin oil Substances 0.000 description 24
- 239000003995 emulsifying agent Substances 0.000 description 24
- 239000007924 injection Substances 0.000 description 23
- 108090001123 antibodies Proteins 0.000 description 22
- 102000004965 antibodies Human genes 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 239000000787 lecithin Substances 0.000 description 21
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 20
- 229940067606 Lecithin Drugs 0.000 description 20
- 235000010445 lecithin Nutrition 0.000 description 20
- 229920000642 polymer Polymers 0.000 description 20
- 238000002156 mixing Methods 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 18
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2S,3R,4S,5R,6R)-3-[(2S,3R,4S,5R,6S)-5-[(2S,3R,4S,5R)-4-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4aR,5R,6aS,6bR,9S,10S,12aR)-10-[(2R,3R,4S, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 17
- 239000012530 fluid Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- NWGKJDSIEKMTRX-AAZCQSIUSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000028993 immune response Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 12
- 230000002163 immunogen Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000005191 phase separation Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 10
- 241000589902 Leptospira Species 0.000 description 10
- 229920000136 polysorbate Polymers 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000002966 Serum Anatomy 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 101710006406 ITA Proteins 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003308 immunostimulating Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001264 neutralization Effects 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 229940031439 Squalene Drugs 0.000 description 6
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 201000002364 leukopenia Diseases 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 235000019271 petrolatum Nutrition 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 230000003389 potentiating Effects 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- 206010049025 Persistent generalised lymphadenopathy Diseases 0.000 description 5
- 229940067631 Phospholipids Drugs 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 235000009001 Quillaja saponaria Nutrition 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 229940115922 Streptococcus uberis Drugs 0.000 description 5
- 241000194054 Streptococcus uberis Species 0.000 description 5
- 101710025653 UL9 Proteins 0.000 description 5
- 206010058874 Viraemia Diseases 0.000 description 5
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2R)-2-[(3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000000227 bioadhesive Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000005591 charge neutralization Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 101700057949 gin Proteins 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000003253 viricidal Effects 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 229940066842 Petrolatum Drugs 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- 241001454523 Quillaja saponaria Species 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- 229940121354 immunomodulators Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic Effects 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000405 serological Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 241000711895 Bovine orthopneumovirus Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010358 genetic engineering technique Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000002519 immonomodulatory Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 229920001888 polyacrylic acid Polymers 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- WXNRAKRZUCLRBP-UHFFFAOYSA-N 2-[3-(dioctadecylamino)propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 2
- 229950010555 AVRIDINE Drugs 0.000 description 2
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 210000001165 Lymph Nodes Anatomy 0.000 description 2
- 230000035633 Metabolized Effects 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 241000514401 Prumnopitys ferruginea Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000727 fraction Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001861 immunosuppresant Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 230000000541 pulsatile Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UGXDVELKRYZPDM-FSEWFXQFSA-N (4R)-4-[[(3R)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)C([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-FSEWFXQFSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (N-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- NFAOATPOYUWEHM-UHFFFAOYSA-N 2-(6-methylheptyl)phenol Polymers CC(C)CCCCCC1=CC=CC=C1O NFAOATPOYUWEHM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- QMHCWDVPABYZMC-MYPRUECHSA-N 3β-hydroxy-23-oxoolean-12-en-28-oic acid Chemical compound C1C[C@H](O)[C@@](C)(C=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C QMHCWDVPABYZMC-MYPRUECHSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 206010000269 Abscess Diseases 0.000 description 1
- 241001665715 Acanthophyllum Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 210000000795 Conjunctiva Anatomy 0.000 description 1
- 241001126268 Cooperia Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 229940026599 Cryptosporidium parvum Drugs 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Polymers OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N Diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 208000003672 Enzootic Bovine Leukosis Diseases 0.000 description 1
- 229960002061 Ergocalciferol Drugs 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N Ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- DNVPQKQSNYMLRS-LNHMRCHQSA-N Ergosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3C([C@H]4[C@@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)=CC=2)CC1 DNVPQKQSNYMLRS-LNHMRCHQSA-N 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 229940097043 Glucuronic Acid Drugs 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 230000036297 Hepatic clearance Effects 0.000 description 1
- 241000606831 Histophilus somni Species 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 229940039371 Karaya Gum Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N L-glucitol Polymers OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010024234 Leptospira infection Diseases 0.000 description 1
- 241001518163 Leptospira interrogans serovar Hardjo-bovis Species 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 229950009571 MURABUTIDE Drugs 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000606268 Morina Species 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 229940114179 Mycobacterium bovis Drugs 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- FSSVIYSWRLKICW-UHFFFAOYSA-N N-ethyl-N-phenylacetamide Chemical compound CCN(C(C)=O)C1=CC=CC=C1 FSSVIYSWRLKICW-UHFFFAOYSA-N 0.000 description 1
- 241001147660 Neospora Species 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 241000243795 Ostertagia Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229940051027 Pasteurella multocida Drugs 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241001092473 Quillaja Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 210000001991 Scapula Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- VXMKYRQZQXVKGB-CWWHNZPOSA-N Tannin Chemical compound O([C@H]1[C@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]([C@H]2O)O1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 VXMKYRQZQXVKGB-CWWHNZPOSA-N 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 229940118701 Toxoplasma gondii Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N Tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 230000036909 Volume distribution Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 150000003937 benzamidines Chemical class 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- ZDSXRJABOCTJTD-HUYBTDLASA-N butyl (2R)-2-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O ZDSXRJABOCTJTD-HUYBTDLASA-N 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000000120 cytopathologic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000601 reactogenic Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229930000044 secondary metabolites Natural products 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
Abstract
This invention provides submicron oil-in water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.
Description
empower the immune response. Many adjuvants modify the network of cytokines associated with immune response. These immunomodulatory adjuvants can exert their effect even when they are not combined with antigens. In general, immunomodulatory adjuvants cause a regulation by general increase of certain cytokines and a concomilanie regulation by decreasing of hearing causing a cellular response Th1 and / or a humoral Th2. Some adjuvants have the ability to preserve the integrity of the configuration of an antigen so that the antigens can be efficiently presented to the appropriate immune cells. As a result of this preservation of the nutrient configuration mediated by the adjuvant formulation, the vaccine would have a longer shelf life than that demonstrated for the immunosuppressant complexes (ISCOM). Ozel M. et al .; Qualernary Structure of the Immunoestimmulafing Complex (Iscom), J. of Ultrastruc. and Molec. Struc. Res. 102, 240-248 (1989). Some adjuvants have the property of retaining the antigen in deposit form in the area of the injection. As a result of this depot effusion, the amphigen is not rapidly lost by hepatic clearance. The aluminum salts and the water emulsions in oil accrue to the effect of this deposition effect with a shorter duration. For example, a long-term depot can be achieved by using Freund's complete adjuvant (FCA) which is a water-in-oil emulsion. The FCA typically remains in the injection zone until biodegradation allows the antigen to be removed by the antigen-presenting cells. Based on their physical nature, adjuvants can be grouped into two very broad categories, specifically particulate adjuvants and non-particulate adjuvants. The particulate adjuvants exist in the form of microparticles. The immunogen is capable of incorporating or associating with the microparticles. Aluminum salts, water emulsions in oil, emulsions of oil in water, immunosimulatory complexes, liposomes and nanoparticles and microparticles are examples of particulate adjuvants. Non-particulate adjuvants are generally immunomodulators and are generally used in June with particulate adjuvants. Muramil dipeptide (a component of the active adjuvant of a pepifidoglycan extracted from Mycobacillus), non-ionic block copolymers, saponins (a complex mixture of extruded fyleerpenoids from the bark of the Quillaja saponaria tree), Lipid A (a glucosamine disaccharide with two phosphate groups and five or six chains of fatty acids generally of C12 to C16 in length), cytokines, carbohydrate polymers, derivatized polysaccharides, and bacterial toxins such as cholera toxin and labile ioxin of E. coli (LT) are examples of non-particulate adjuvants . Some of the best-known adjuvants are combinations of non-particulate immunomodulators and particulate materials that could confer a depot effect to the adjuvant formulation. For example, FCA combines the immunomodulatory properties of components of Mycobacterium tuberculosis with the short-term deposition effect of oil emulsions. Oil emulsions have been used as vaccine adjuvants for a long time. Le Moignic and Pinoy found in 1916 that a suspension of inactivated Salmonella typhimurium in paraffin oil increased the immune response. Subsequently, in 1935, Ramón described starch as one of the substances that increased the antimicrobial response to the diphtheria dioxoid. However, oil emulsions did not become popular until 1937 when Freund achieved his formulation of adjuvant, which is now known as Freund's Adjuvant Complement (FCA). The FCA is an emulsion of water in oil composed of mineral oil (paraffin) mixed with inactivated Mycobacteria and Arlacel A. Arlacel A is mainly monooleate of mannide and is used as an emulsionanfe agent. Although FCA is excellent for inducing an antibody response, causes severe pain, abscess formation, fever and granulomatous inflammation. To avoid these undesirable side reactions, the Incomplete Freund's Adjuvant (IFA) was developed. The IFA is similar to the FCA in its composition except for the absence of mycobacterial components. The IFA acíúa medlanfe formulation in depósiío in the area of the injection and liberation lenía of the aníígeno simulating the producing cells of aníibodies. Another strategy to improve FCA was based on the notion that replacing paraffin oil with a biocompatible oil would help eliminate FCA-associated reactions in the injection area. It was also believed that the emulsion should be one of oil in water instead of water in oil because that produces a long-term deposit in the area of the injection. Hilleman et al, described an Adjuvant 65 oil based adjuvant, which consisted of 86% peanut kernel, 10% Arlacel A as an emulsifier and 4% aluminum monoesiearafoxide as a destabilizer. Hilleman, 1966, Prog. Med. Viral. 8: 131-182; Hilleman and Beale, 1983, in New Approaches I Vaccine Developmení (Editors Bell, R. and Torrigiani, G.), Schwabe, Basel. In humans, the use of Adjuvaní 65 was safe and powerful, but it had less adjuvant capacity than the IFA. However, the use of Adjuvant 65 was suspended due to the reactogenic capacity in man with certain batches of vaccines and the reduction of adjuvant capacity when purified or synthetic emulsifier was used in place of Arlacel A. US Pat. 5,718,904 and 5,690,942 teach that the paraffin oil in the water-in-water emulsion can be suspended by meabolizable oil in order to improve the safety profile. In addition to adjuvant capacity and safety, the physical appearance of an emulsion is also an important commercial consideration. The physical aspect depends on the emulsion's stability. Phase separation, sedimentation and coalescence are indicators of the instability of the emulsion. Phase separation occurs when the oleaginous and aqueous phases of the emulsion have a different specific gravity. Phase separation also occurs when the droplet size of the emulsion is large and the emulsion does not have Brownian movement. When the size of the drop is large, there is a tendency for the interface to break and the drops merge into large particles. The stability of the emulsion is determined by a number of natural factors such as the nature and amount of emulsifier used, the size of the gouge in the emulsion and the difference in density between the oil and water phase. The emulsifiers promote the stabilization of dispersed goites reducing the free energy of the inferic and creating physical or electrophysical barriers to the coalescence of the goias. Nonionic as well as ionic detergents have been used as emulsifiers. The nonionic emulsifiers are oriented in the infervescence and produce relatively voluminous esírucfuras, which entails the spherical evolution of the dispersed goies. The anionic or cationic emulsifiers induce the formation of a double electric layer by reducing the conjugated ions; the repellent forces of the double layer cause the drops to repel one another as they approach. In addition to using emulsifiers, the stability of the emulsion can also be achieved by reducing the size of the emulsion gouge by mechanical means. Typically, propellant mixers, turbine rotors, colloid mills, homogenizers, and ultrasonic devices have been used to make emulsions. Microfluidization is another way to increase the homogeneity of the size of the gouge in the emulsion. Microfluidization can produce an elegant, physically flammable emulsion with a particle size consistent in the submicrometric range. In addition to increasing emulsion stability, the microfluidization process allows for final filtration which is a preferred way of ensuring the sterility of the final product. In addition, the submicromergic oil particles can pass from the injection sites to the lymphatics and then to the lymph nodes of the drainage, blood and spleen chain. This reduces the likelihood of isolating an oil deposit in the area of the injection that can produce local inflammation and a significant reaction in the area of the injection. Microfluidizers are now commercially available.
The formation of emulsions is produced in a microfluidizer by introducing two fluidized jets at high velocities in an interaction chamber. The microfluidizer is driven by air or nilrogen and can operate with internal pressures above 137,900 kPa. U.S. Patent 4,908,154 teaches the use of a microfluidizer to obtain emulsions essentially free of any emulsifying agents. A number of submicromerial water adjuvant formulations in water have been described in the literature. U.S. Patent 5,376,369 describes a submicron emulsion adjuvant of oil in water which is known as Syntax Adjuvanf Formulafion (SAF). SAF contains squalene or squalane as an oleaginous component, a polymericity of Pluronic block polymer L121 (polyoxypropylene and polyoxyethylene) which forms emulsions and a nimmunopoinizing canine of muramyl dipépfide.
Squalene is a precursor of linear hydrocarbon colesferol that is found in many tissues, nobly in the liver of fish and other sharks. Squalane is prepared by hydrogenation of squalene and is completely purified. Tancula squalene such as squalane can be metabolized and have a good background in toxicological studies. Squalene and squalane emulsions have been used in vaccines against cancer in humans with mild side effects and with a desirable efficacy. See, for example, Anthony C. Allison, 1999, Squalene and Squalane emulsions as adjuvants, Methods 19: 87-93. US Pat. No. 6,299,884 and International Patent Publication WO 90/14837 teach that polyoxypropylene and polyoxy-ethylene block copolymers are not essential for the formation of submicron emulsions of oil in water. In addition, these references teach the use of non-toxic melabolizable oil and expressly exclude the use of paraffin oil and toxic petroleum oil oils in their emulsion formulations. U.S. Patent 5,961,970 describes another submicron emulsion of oil in water for use as adjuvant in vaccines. In the emulsion described in this patent, the hydrophobic component is selected from the group consisting of a medium-chain glyceride oil, a vegetable oil and a mixture thereof. The surfactant that is included in this emulsion may be a biologically comparative, non-ionic agent such as a phospholipid (for example lecltin) or a pharmaceutically acceptable non-naive medical agent such as TWEEN-80. This patent teaches also the incorporation of the antigen to the emulsion at the moment in which the emulsion is formed, contrasted with the mixture of the anígen with the emulsion after the emulsion has been formed independently and exirinseca. U.S. Patent 5,084,269 teaches that an adjuvant formulation containing leciin combined with paraffin oil causes a decrease in irritation in the host animal and simultaneously induces an increased seismic immunity. The formulation of the adjuvant resulting from U.S. Patent 5,084,269 is commercially used in veterinary vaccines under the trade name AMPHIGEN®. The formulation of AMPHIGEN® is formed by micelles - oil gofas surrounded by lecithin. These micelles allow more complete cellular anigenes to bind than the adjuvant ones with oleaginous base. In addition, formulations of AMPHIGEN®-based vaccines contain a low oil content of 2.5 to 5% paraffin wax, compared to other formulations of vaccines containing oleaginous adjuvants, which typically contain 10% to 20% oil Its low oil content makes this adjuvant-based vaccine less irritating to the tissues in the injection site, resulting in fewer injuries and less waste when sacrificed. In addition, the lecithin coating surrounding the oil droplets further reduces reactions in the injection site resulting in a vaccine that is safe as well as effective. The formulation of AMPHIGEN® is used as adjuvant in a number of veterinary vaccines and there is a need to maintain the physical appearance of the vaccine during short and long storage periods as well as at the time of reconstitution. further, a lyophilized antigen is mixed with the adjuvant formulation prepared previously just before the injection. This practice does not always ensure that there is a uniform distribution of the antigen in the emulsion of oil in water and the appearance of the emulsion may not be desirable. In addition, when standing, the homogenized emulsion may show phase separation. Therefore, there is a need for a stable adjuvant formulation that does not reveal phase separation over a long shelf life. One way to prevent phase separation is to reduce the size of the glaze and increase the homogeneity of the emulsion particles. Although the process of microfluidization of meta bolite oil-based emulsion formulations has been documented, microfluidization of acetyl emulsions in water has not yet been carried out as the AMPHIGEN® formulation. In the present invention, microfluidization has been used to bring the size of the paraffin oil goiters surrounded by lecithin to submicron size. Unexpectedly, the present inventors have discovered that microfluidization of vaccine formulations with adjuvants of an oil-in-water emulsion formed by a mixture of leciin and oil not only improves the physical appearance of the formulations, but also enhances the effects immunizers of the formulations. The microfluidized formulations are also characterized by an improved safety profile.
BRIEF DESCRIPTION OF THE INVENTION
The present inventors have unexpectedly discovered that the adjuvant activity and the safety profile of non-metabolizable oil-based oil emulsions in water can be improved by microfluidization. The antigens that are incorporated into the microfluidized emulsions are stable even when the antigens are intrinsically incorporated into the emulsions before microfluidization. Accordingly, in one embodiment, the present invention provides formulations of oil-in-water submicron emulsions useful as vaccine adjuvants. The oil-in-water submicron emulsions of the present invention are compounded by a non-meabolizable oil, at least one surfactant and an aqueous component, in which the oil is dispersed in the aqueous component with an average size of the oil golas in the submicrometric interval. A preferred non-meyabolizable oil is fluid paraffin oil. Preferred surfactants include lecithin, Tween-80 and SPAN-80. A preferred water-in-oil emulsion provided by the present invention is compounded by an AMPHIGEN® formulation.
The oil-in-water emulsions of the present invention may include additional components that are appropriate and desirable, including preservatives, osmotic agents, bioadhesive molecules and immune-limiting molecules. Preferred immunosuppressant molecules include, for example, Quil A, cholesterol, GPI-0100, dimethyl diacid bromide (DDA). In another embodiment, the present invention provides methods for preparing a submicroméral oil-in-water emulsion. In accordance with the present invention, the various components of the emulsion are mixed, including the oil, one or more lensioacids, an aqueous component and any other component suitable for use in the emulsion. The mixture is subjected to a primary emulsification process to form an oil-in-water emulsion, which is then passed through a microfluidizer to obtain an oil-in-water emulsion of goats with a diameter of less than 1 micrometer, preferably with an average size of drops below 0.5 micrometers. In yet another embodiment, the present invention provides compositions of vaccines that contain an antigen and a submicromerric emulsion of oil in water described above. The anigen is incorporated into the emulsion exírinseca or inírínseca, preferably in an intrinsic manner. The antigen that can be included in the compositions of the vaccines of the present invention can be a bacterial, fungal or viral antigen or a combination thereof. The antigen can take the form of an inactivated preparation of whole or partial cells or viruses, or have the form of antigenic molecules obtained by conventional protein purification, genetic engineering techniques or chemical synthesis. In a further embodiment, the present invention provides methods for preparing compositions of vaccines containing an antigen or combined antigens (s) with a submicron emulsion of oil in water. In order to prepare the compositions of the vaccines of the present invention, the antigen (s) can be combined in an intrinsic manner (for example before microfluidization) or extrinsically (for example after microfluidization) with the components of the oil in water emulsion. Preferably, the antigen is combined with the components of the oil emulsion in water in an inhysninic manner. In still another embodiment, the present invention provides compositions of vaccines conferring a microencapsulated anion and an oil-in-water submicron emulsion described above, in which the microencapsulated anion is combined with the emulsion in an extrinsic manner. It has also surprisingly been found that a saponin and a sterol, when combined in solution, they are associated with yes to form complexes in the form of helical micelles. In accordance with the present invention, these helical micelle complexes have immunostimulatory properties and are especially useful as adjuvants in vaccine compositions. Accordingly, the present invention provides compositions of vaccines containing a saponin and a eseryol, in which saponin and eserol form complexes in the form of helical micelles. The present invention also provides compositions comprising a saponin, a seriol and an anigen, wherein the saponin and the eserol form complexes in the form of helical micelles and in which the antigen is mixed but not incorporated into the helical micelles.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the process for batch preparation of non-microfluidized vaccine compositions. In this procedure the various components of the vaccine are added to the addition vessel on the left and finally pumped into the mixing vessel where the components are mixed by simple mechanical means. Figure 2 represents the process for the preparation of compositions of the microfluidized vaccines containing the antigen incorporated in an inverse way. The various components of the vaccine are added to the addition vessel and transferred to the pre-emulsion mixing unit for mixing by simple mechanical means. Subsequently, the emulsion is passed through a microfluidizer and collected in the post-microfluidization chamber. Figure 3 represents the distribution of the size of the vaccines of the non-microfluidized AMPHIGEN® formulation-based vaccine, the microfluidized AMPHIGEN® formulation-based vaccine and the preparation of the vaccine mixed in a bank. Figure 4 shows the absence of phase separation in the preparation of microfluidized vaccine. Figure 5 represents a comparison of the stability of the antigens that are incorporated in a non-inverse manner to the preparation of the vaccine based on the formulation of AMPHIGEN® microfluidized (A907505) and fresh preparations of the vaccines based on formulation of AMPHIGEN® non-microfluidized conírol (A904369, A904370 and A904371). The preparations of the vaccines were stored at 4 ° C for two years. At different times during storage (0, 6, 12 or 24 months), the formulations were used to vaccinate cows of months of age.
Vaccination was carried out on Day 0 and 21 with 2 ml of a vaccine dose and the sera were collected two weeks after the second vaccination. The assessment of neutralizing antibodies for the BVD virus was determined
Type II in each of the serum samples. Damages are presented in terms of the geometric mean of 5 animals. Figure 6 shows the mean of least squares of the rectal temperature of cattle before and after the administration of microfluidized and non-microfluidized vaccines. T01: Placebo group - single dose; Placebo Group - Double Dose; T03: Non-microfluidized formulation - Single dose; T04: Non-microfluidized formulation - Double dose; T05: Microfluidized formulation - single dose; T06: Microfluidized formulation - double dose. Figure 7 represents the average of the least squares of injection reaction volumes observed in cattle after administration of microfluidized and non-microfluidized vaccines. T03: Non-microfluidized formulation - Single dose; T04: Non-microfluidized formulation - Double dose; T05: Microfluidized formulation - single dose; T06: Microfluidized formulation - double dose. Figure 8 represents the geometric mean of the IgG titers for PauA recombinant aniigen of Streptococcus uberis iras vaccination with the various formulations of vaccines containing PauA recombinant anigen as an antigen of E. coli cells. Figure 9 represents the geometrical average of the IgG titers for E. coli cell antigens of Streptococcus uberis iras vaccination with the various formulations of the vaccines containing recombinant PauA antigen tannin as an E. coli whole cell antigen. Figures 10A and 10B depict the particle size distribution of a microfluidized Amphigen formulation at the start of production (Figure 10A) and 22 months after production (Figure 10B). Figure 11 is a photograph of electron microscopy showing helical micelles formed with Quil A micelles and cholesterol crystals. Figure 12 is a photograph of electron microscopy showing helical immunogenic complexes formed by Quil A and cholesterol on the surface of the BVD Type I antigen.
DETAILED DESCRIPTION OF THE INVENTION
The present inventors have unexpectedly discovered that microfluidization of formulations of vaccines with oil-in-water emulsion adjuvants composed of a mixture of lecithin and paraffin oil not only improves the physical appearance of vaccine formulations, but also it also enhances the immunizing effects of the vaccine formulations. Microfluidized bottle formulations are also characterized by an improved safety profile. Based on these findings, the present invention provides oil-in-water submicron emulsions useful as adjuvants in vaccine compositions. Methods are also provided to prepare these submicromergic emulsions of aceifee in water using a microfluidizer. In addition, the present invention provides compositions of submicromergic vaccines in which an anigen is combined with a submicron emulsion of oil in water. Methods for preparing such vaccine compositions are also provided. The present invention further provides compositions of vaccines containing microencapsulated antigens combined with a submicron emulsion of oil in water and methods for preparing vaccines. To make the description clearer, and not by way of limitation, the detailed description of the invention is divided into the following subsections which describe or illustrate certain characteristics, embodiments or applications of the invention.
Sub-micron oil-in-water emulsions In one embodiment, the present invention provides oil-in-water submicron emulsions useful as vaccine adjuvants. The oil-in-water submicron emulsions of the present invention enhance the immunogenic capacity of the antigens of the vaccine compositions, are safe to be administered to animals and remain stable during storage. The oil-in-water submicron emulsions of the present invention are composed of a non-metabolizable oil, at least one surfactant and an aqueous component, in which the oil is dispersed in the aqueous component with an average size of the oil droplets in the oil. submicrometric interval. By "submicroméírico" it is meant that the goias are of a size less than 1 μm (micrometer) and the average size of the oil drops is less than 1 μm. Preferably, the average droplet size of the emulsion is less than 0.8 μm; more preferably less than 0.5 μm; and even more preferably less than 0.4 μm or approximately 0.1-0.3 μm. The "average droplet size" is defined as the size of the particles of the mean volume diameter (DMV) in a volume distribution of the particle sizes. The DMV is calculated by multiplying each particle diameter by the volume of all particles of that size and adding. This is then divided by the total volume of all the particles. The term "non-metabolizable oil" as used herein refers to oils that can not be metabolized by the body of the animal subject to which the emulsion is administered. The terms "animal" and "animal subject" as used herein refer to all non-human animals, including cattle, sheep and pigs for example. The non-metabolizable oils suitable for use in the emulsions of the present invention include alkenes, alkenes, alkynes and their corresponding acids and alcohols, their ethers and esters, and mixtures thereof. Preferably, the individual compounds of the oil are light hydrocarbon compounds, ie, the components of that type have from 6 to 30 carbon atoms. The oil can be synthetically prepared or purified from petroleum products. Preferred non-metabolizable oils for use in the emulsions of the present invention include mineral oil, paraffin oil and cycloparaffins for example. The term "paraffin oil" refers to a mixture of liquid hydrocarbons obtained from petrolatum by a distillation technique. The term is synonymous with "liquid paraffin", "liquid petrolatum" and "white paraffin oil". The term is intended to also include "fluid paraffin oil", that is, oil that is similarly made by petrolatum distillation but that has a specific gravity slightly less than petrolatum. See, for example, Remington's Pharmaceutical Sciences, 18th Edition (Easinio, Pa.; Mack Publishing Company, 1990, pages 788 and 1323). The paraffin oil can be obtained in various commercial sources, for example J.T. Baker (Phillipsburg, PA), USB Corporation (Cleveland, OH). The preferred paraffin oil is the fluid paraffin oil commercially available under the name DRAKEOL®. Typically, the oleaginous component of the submicron emulsions of the present invention is present in an amount of 1% or 50%) by volume; preferably, in an amount of 10% to 45; more preferably in an amount of 20% to 40%. The oil-in-water emulsions of the present invention typically include at least one (i.e., one or more) surfactant. The surfactants and emulsifiers, terms that are used interchangeably herein, are agents that stabilize the surface of the oil droplets and keep the oil droplets to the desired size. Suitable surfactants for use in the present emulsions include natural biologically compatible surfactants and non-natural synthetic surfactants. Biologically compatible surfactants include phospholipid compounds or a mixture of phospholipids. Preferred phospholipids are phosphatidyl cholines (lecithin), such as soy or egg lecithin. Lecithin can be obtained in the form of a mixture of phosphatides and triglycerides by washing crude vegetable oils with water, and separating and drying the resulting hydrated gums. A refined product can be obtained by fractionating the mixture to obtain the phospholipids and acetone insoluble glycolipids that remain after removing the triglycerides and the vegetable oil by washing with acetone. Alternatively, lecithin can be obtained in various commercial sources. Other suitable phospholipids include phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidic acid, cardiolipin and phosphatidylethanolamine. Phospholipids can be isolated from natural sources or conventionally synthesized. Non-natural synthetic surfactants suitable for use in the submicron emulsions of the present invention include non-ionic surfactants with sorbitan base, for example sorbitan surfactants substituted with fatty acids (commercially available under the name SPAN® or ARLACEL®), fatty acid esters of polyethoxylated sorbitol (TWEEN®), polyethylene glycol esters of fatty acids from sources such as castor oil (EMULFOR); polyethoxylated fatty acid (for example stearic acid available under the name SIMULSOL M-53), polyethoxylated isooctylphenol polymer and formaldehyde (TYLOXAPOL), ethers of polyoxyethylene fatty alcohols (BRIJ®); polyoxyethylene nonphenyl ethers (TRITON® N), polyoxyethylene isocycylphenyl ethers (TRITON® X). Preferred synthetic tensides are the surfactants available under the name SPAN® and TWEEN®. Preferred tensio-acids for use in the oil-in-water emulsions of the present invention include lecithin, Tween-80 and SPAN-80. In general, the surfactant, or combination of surfactants, if two or more surfactants are used, is present in the emulsion in an amount of 0.01% to 10% by volume, preferably from 0.1% to 6.0%, more preferably 0.2% by volume. 5.0% The aqueous component consti- tutes the coninuous phase of the emulsion and may be water, pH regulated saline or any other suitable aqueous solution. The oil-in-water emulsions of the present invention may include additional components that are appropriate and desirable, including preservatives, osmotic agents, bioadhesive molecules, and immunostimulatory molecules. It is believed that bioadhesive molecules can potentiate the administration and binding of antigens on or through the target mucosal surface conferring mucosal immunity. Examples of suitable bioadhesive molecules include non-natural acidic polymers such as polyacrylic acid and polymethacrylic acid (e.g. CARBOPOL®, CARBOMER); synthetic modified acidic polymers such as carboxymethylcellulose; syntectically neutral modified natural polymers such as (hydroxypropyl) methylcellulose; polymers that carry basic amines such as chitosan; acidic polymers obtainable from natural sources such as alginic acid, hyaluronic acid, pectin, gum tragacanth and karaya gum; and natural non-natural neutral polymers, such as polyvinyl alcohol; or their combinations. The phrase "immunostimulatory molecules", as used herein, refers to molecules that enhance the immune protective response induced by an antigen component in the vaccine compositions. Suitable immunosorbent materials include bacterial cell wall compounds, for example N-acetylmuramyl-L-alanyl-D-isoglutamine derivatives such as murabutide, threonyl-MDP and tripiplymuramuram; saponin glycosides and their derivatives, for example Quil A, QS 21 and GPI-0100; cholesterols and quaternary ammonium compounds, for example dimethyldiocylammonium bromide (DDA) and N, N-dioctadecyl-N, N-bis (2-hydroxyethyl) propanediamna ("avridine"). Saponins are glycosidic compounds that are produced as secondary metabolites in a wide variety of plant species. The chemical structure of saponins confers a wide range of pharmacological and biological activities, including some potent and effective immunological activity.
Structurally, saponins are constituted by any aglucone linked to one or more chains of sugars. Saponins can be classified according to their agglutin composition: triterpenic glycosides, steroidal glycosides and steroidal alkaloid glycosides. Saponin can be isolated from the bark of Quillaja saponaria.
Saponin has long been known as an immunostimulator. Dalsgaard, K., "Evaluation of adjutant activity with special reference to the application in the vaccination of cattle against foot-and-mouth disease", Act. See. Scand. 69: 1-40 1978. The crude extracts of plants containing saponins improved the potency of foot-and-mouth disease vaccines. However, crude extracts were associated with adverse side effects when used in vaccines. Subsequently, Dalsgaard partially purified the active component of the saponin adjuvant by dialysis, ion exchange and gel filtration chromatography. Dalsgaard, K. and cois. "Saponin Adjuvants III Isolation of a substance from Quillaja saponaria Morina with adjuvant activity in foot-and-mouth disease vaccines", Aren. Gesamte. Virusforsch. 44: 243-254 1974. An aqueous adjuvant component purified in this way is known as "Quil A". Based on weight, Quil A demonstrated increased potency and showed reduced local reactions when compared to crude saponin. Quil A is widely used in veterinary vaccines. Further analysis of Quil A by high performance liquid chromatography (HPLC) revealed a heterogeneous mixture of very similar saponins and led to the discovery of QS21 which was a potent adjuvant with reduced or minimal toxicity. Kensil C.R. et al., "Separation and characíerizafion of saponins with adjuvant activity from Quillaja saponaria Molina cortex", J. Immunol. 146: 431-437, 1991. In contrast to most other immunostimulators, QS21 is soluble in water and can be used in vaccines with or without emulsion-type formulations. It has been shown that QS21 elicits a Th1-like response in mice by stimulating the production of IgG2 and IgG2b antibodies and induced antigen-specific CD8 + CTL (MHC class I) in response to subunit antigens. Clinical studies in humans have shown their capacity as an adjuvant with an acceptable toxicological profile. Kensil, C.R. et al., "Structural and immunological characterization of vaccine adjuvant QS-21, In Vaccine Design: the subunit and Adjuvaní Approach," Editors Powell, M.F. and Newman, M.J. Plenum Publishing Corporation, New York 1995, pages 525-541. U.S. Patent 6,080,725 teaches methods for preparing and using saponin and lipophilic conjugate. In this saponin and lipophilic conjugate, a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or irepene is covalently linked to a triterpenic saponin not adhered or deacylated by a carboxy group present in the 3-O-glucuronic acid of the triterpene saponin . The binding of a lipophilic moiety to 3-O-glucuronic acid of a saponin such as Quillaja's desacylsaponin, P-lucioside or Gypsophila saponin, saponaria and Acanthophyllum enhances its adjuvant effects on humoral and cell-mediated immunity.
In addition, the binding of a lipophilic moiety to the 3-O-glucuronic acid moiety of a non-adiated or deacylated saponin provides a saponin analog that is easier to purify, less toxic, chemically more stable and possesses properties as an adjuvant or better than the original saponin. GPI-0100 is a saponin and lipophilic conjugate that is described in United States Patent 6,080,725. GPI-0100 is produced by the addition of an aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid. Quaternary ammonium compounds - A number of aliphatic nitrogenous bases have been proposed for use as immunological adjuvants, including amines, quaternary ammonium compounds, guanidines, benzamidines and tiouronios. Specific compounds of that type include dimethyldioctadecylammonium bromide (DDA) and N, N-dioctadecyl-N, N-bis (2-hydroxy-yl) -propanediamine ("avridine"). U.S. Patent 5,951,988 teaches an adjuvant formulation containing quaternary ammonium salts such as DDA together with an oleaginous component. This formulation is useful together with known immunological substances, for example viral or bacterial antigens in a vaccine composition, to enhance the immunogenic response. The composition is also useful without an antigen incorporated as a nonspecific nonsostimulatory formulation. U.S. Patent 4,310,550 discloses the use of N, N-higher alkyl-N, N'-bis (2-hydroxy-yl) propanediamna, and N, N-higher alkyl-xylylenediamines formulated with fat or lipid emulsion as adjuvant of vaccines. A method for inducing or enhancing the immunogenic response of an antigen in man or an animal by parenteral administration of the adjuvant formulation is described in U.S. Patent 4,310,550. In a preferred embodiment, the present invention provides a submicron oil-in-water emulsion useful as a vaccine adjuvant, which is composed of an AMPHIGEN® formulation, with droplets of a size less than 1 μm and an average droplet size of approximately 0.25 μm. The term "AMPHIGEN® formulation" as used herein refers to a solution formed by mixing a solution of DRAKEOL® leciin oil (Hydronics, Lincoln, NE) with saline in the presence of TWEEN® 80 and SPAN® 80. A typical AMPHIGEN® formulation contains 40% fluid paraffin oil >; in volume (v / v), approximately 25% w / v of lecithin, approximately 0.18% by volume (v / v) of TWEEN 80 and approximately 0.08% > in volume (v / v) of Span 80.
Means for preparing submicron emulsions of oil in water In another embodiment, the present invention provides methods for preparing the submicron emulsions of oil in water described above.
In accordance with the present invention, the various components of the emulsion, including the oil, one or more surfactants, an aqueous component and any other suitable component for use in the emulsion are combined and mixed together. The mixture formed is subjected to an emulsification process, typically by passing one or more times through one or more homogenizers or emulsifiers to form an oil-in-water emulsion which has a uniform appearance and a mean size of the gums of approximately 0.5 μm. . For this purpose any commercially available homogenizer or emulsifier can be used, for example Ross emulsifier (Hauppauge, NY), Gaulin homogenizer (Everetí, MA). The emulsion thus formed is then subjected to microfluidization to bring the size of the goies to the submicron range. Microfluidization can be achieved using a commercial microfluidizer such as model number 110Y available from Microfluidics, Newton, Mass; the model 30CD of Gaulin (Gaulin, Inc., Evereíí, Mass.); and Rainnie Minilab at 8.30 am (Miro Alomizer Food and Dairy Inc., Hudson, Wis.). These microfluidizers operate by forcing the fluids through small openings at elevated pressure, in such a way that the two fluid jets move at high velocities in an interaction chamber to form emulsions with beams of a submicron size. The size of the drop can be determined by a variety of methods known in the art, for example, laser diffraction, using commercially available measuring instruments. The size may vary depending on the type of lens used, the ratio of surfactant to oil, the pressure at which it is worked, the temperature and the like. The expert in the art can determine the desired combination of these parameters to obtain emulsions with the desired droplet size without undue experimentation. The gofas of the emulsions of the present invention have a diameter of less than 1 μm, preferably a mean size of the gouges of less than 0.8 μm, and more preferably an average size of the drops of less than 0.5 μm, and even more preferably of an average size of the drops lower than 0.3 μm. In a preferred embodiment of the present invention, the DRAKEOL lecithin oil solution, which is commercially available from Hydronics (Lincoln, NE) and contains 25% leciin in fluid paraffin oil, is combined and mixed with saline as well as with the TWEEN® 80 and SPAN® 80 agents to form an "AMPHIGEN® solution" or "AMPHIGEN® formulation". The AMPHIGEN® solution is then emulsified with a Ross® emulsifier (Hauppauge, NY 11788) at approximately 3400 rpm to form a water-in-oil emulsion. Subsequently the emulsion is passed once through a Microfluidizer working at 31.027.5 kPa ± 3.447.5 kPa. The oil-in-water emulsion contains beads less than 1 μm in size, with an average droplet size of approximately 0.25 μm.
Compositions of Vaccines Containing Antigens Incorporated in Submicroméeric Oil-in-Water Emulsions In another embodiment, the present invention provides compositions of vaccines that contain an antigen (s) and a submicromer emulsion of oil in water described above. These compositions of the vaccines are characterized in that they have an enhanced immunogenic effect and an improved physical appearance (for example, phase separation is not observed after a long period of storage). In addition, the compositions of the vaccines of the present invention are safe for administration to animals. According to the present invention, the enzyme can be combined with the emulsion in an extrinsic or, preferably, in an irresistible way. The term "nirinase" refers to the process in which the antigen is combined with the components of the emulsion prior to the microfluidization step. The term "ex-insulin" refers to the process in which the antigen is added to the emulsion after the emulsion has been microfluidized. The antigen added extrinsically may be free antigen or may be encapsulated in microparticles as described in more detail below. The term "antigen" as used in the present specification refers to any molecule, compound or composition that is immunogenic in an animal and is included in the vaccine composition to elicit a pro-cyclic immune response in the animal to which it is administered. the vaccine composition. The term "immunogenic" as used in connection with an animal refers to the ability of the animal to elicit an immune response in an animal conferred by the animal. The immune response may be a primordially mediated cellular immune response by cytoxic T lymphocytes, or a humoral immune response primarily mediated by cooperating T-lymphocytes, which in turn acylate B-lymphocytes that cause the production of antibodies. An "immune pro-cyclic response" is defined as any immune response, either antibody-mediated or cell-mediated immune response, or both, that occurs in the animal that prevents or reduces detectable appearance or eliminates or reduces detectable severity, or slows down in a detectable way the speed of progression, the disorder or disease caused by the antigen or a pathogen that contains the antigen. The antigens which may be included in the vaccine composition of the present invention include antigens prepared from pathogenic bacteria such as Mycoplasma hyponeumoniae, Haemophilus somnus, Haemophilus parasuis, Bordetella bronchiseptica, Actinobacillus pleuropneumonie, Pasteurella multocida, Manheimia hemolitica, Mycoplasma bovis, Mycoplasma galanacieum. , Mycobacterium bovis, Mycobacterium paratuberculosis, Clostridial spp., Streptococcus uberis, Streptococcus suis, Staphylococcus aureus, Erysipelothrix rhusopathiae, Campylobacter spp., Fusobacterium necrophorum, Escherichia coli, Salmonella enterica serovars, Leptospira spp.; pathogenic fungi such as Candida; protozoa such as Cryptosporidium parvum, Neospora canium, Toxoplasma gondii, Eimeria spp .; helminths such as Ostertagia, Cooperia, Haemonchus, Fasciola, either in the form of an inacíivated or partial cell preparation or in the form of antigenic molecules obtained by conventional protein purification, genetic engineering techniques or chemical synthesis. Additional antigens include viral pathogenic viruses such as bovine herpesvirus 1, 3, 6, bovine viral diarrhea virus (BVDV), lipos 1 and 2, bovine pseudoinfluenza virus, bovine respiratory syncytial virus, bovine leukosis virus, rinderpest virus, foot-and-mouth disease virus, rabies, swine virus, African swine fever virus, porcine parvovirus, PRRS virus, porcine circovirus, influenza virus, porcine vesicular disease virus, Techen fever virus, pseudorbism virus, either in the form of a preparation of whole inactivated or partial viruses, or in the form of antigenic molecules obtained by conventional protein purification, genetic engineering techniques or chemical synthesis. The amount of the antigen must be such that the antigen, combined with the oil in water emulsion, is effective to induce a protective immune response in an animal. The precise amount for an effective antigen depends on the nature, activity and purity of the antigen and can be determined by those skilled in the art. The amount of oil in water emulsion present in the vaccine compositions should be sufficient to enhance the immunogenic capacity of the antigen (s) in the vaccine compositions. When desirable and appropriate, additional amounts of surfactant (s) or additional surfactant (s) may be added to the vaccine composition in addition to the surfactant (s) provided by the emulsion of aceifeide in water. Generally, the oleaginous component is present in the final volume of a vaccine composition in an amount of 1.0% to 20% or by volume; preferably at a rate of 1.0% to 10% >; more preferable in a rate of 2.0% to 5.0%. The density, or the combination of nutrients if two or more substances are used, is present in the final volume of a vaccine composition in a quantity of 0.1%) to 20% by volume, preferably 0.15%) to 10%, more preferably 1.2% to 6.0%. In addition to the enzyme (s) and the emulsion of oil in water, the vaccine composition may include other components that are appropriate and desirable, such as preservatives, osmoic agents, bioadhesive molecules, and immunostimulatory molecules (eg, Quil A). , cholesterol, GPI-0100, dimethyldiocylammonium bromide (DDA)), as described above in relation to the oil in water emulsion. The compositions of the vaccines of the present invention can also include a veterinarily acceptable vehicle. The term "an acceptable carrier vehicle" includes any and all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, silicone agents, adsorption retarding agents, and the like. The diluyenles may include water, saline, dextrose, ethanol, glycerol and the like. Isotonic agents may include sodium chloride, dextrose, mannitol, sorbifol and lactose in other. Stabilizers include albumin in others. In a preferred embodiment, the present invention provides a vaccine composition that includes at least one of a BVDV type I or BVDV type II antigen, which is intrinsically incorporated into an oil-in-water emulsion which is sized less than 1 μm, preferably of an average size of the gouges of less than 1.8 μm, more preferably less than 1.5 μm, and even more preferably of an average droplet size of about 1.5 μm. The BVDV antigen I I and / or II is preferably in the form of a viral activated preparation. The submicron emulsion of oil in water is preferably composed of an AMPHIGEN® formulation (ie, a formulation containing fluid paraffin oil, lecithin, TWEEN® 80 and SPAN® 80). The vaccine composition preferably also includes Quil A, cholesterol and thimerosol. In another preferred embodiment, the present invention provides a vaccine composition that includes a Lepfospira anígen and at least one of a BVDV ipo I or BVDV type II anigen in an oil-in-water emulsion. The antigens, preferably in the form of an inactivated cellular or viral preparation, are incorporated intrinsically into the submicron emulsion of oil in water having droplets of less than 1 μm in size.; preferably of a mean gage size of less than 1.8 μm, more preferably less than 1.5 μm, and even more preferably of an average gum size of about 1.5 μm. The submicroméric emulsion of oil in water is preferably composed of an AMPHIGEN® formulation (ie, a formulation containing fluid paraffin oil, lecithin, TWEEN® 80 and SPAN® 80). The vaccine composition preferably also includes one or more immunosphimulatory molecules which are selected from Quil-A, cholesterol, DDA, GPI-100 and aluminum hydroxide (AIOH). In yet another preferred embodiment, the present invention provides a vaccine composition that includes at least one bacterial agent, for example the PauA protein of recombinant Streptococcus uberis or an E. coli cell preparation or a combination of both in an emulsion of oil in water. The antigen (s) is intrinsically combined with the submicron emulsion of oil in water having droplets of size less than 1 μm, preferably of an average size of the goias less than 1.8 μm, more preferably lower at 1.5 μm, and even more preferably from an average droplet size of approximately 1.25 μm. The submicron oil-in-water emulsion is preferably composed of an AMPHIGEN® formulation (ie, a formulation containing fluid paraffin oil, lecillin, TWEEN® 80 and SPAN® 80). The vaccine composition preferably also includes one or more immunostimulatory molecules that are selected from Quil-A, DDA, GPI-100. The compositions of the vaccines of the present invention can be administered to an animal by known routes, including oral, inanal, mucosal, topical, transdermal and parenteral (for example intravenous, iniraperitoneal, nfradermal, subcutaneous or intramuscular). Administration can be achieved using a combination of routes, for example the first administration using a parenteral route and subsequent administration using a mucosal route.
Means for preparing compositions of vaccines In a further embodiment, the present invention provides methods for preparing compositions of vaccines conferring an antigen or antigens and a submicromerric emulsion of oil in water. To prepare the compositions of the vaccines of the present invention, the antigen (s) can be combined intrinsically or extrinsically with the components of the oil in water emulsion.
Preferably, the antigen is combined with the components of the oil-in-water emulsion in an intrinsic manner. The antigen can be combined with the various components of the emulsion, including oil, one or more compounds, an aqueous component and any other suitable component to form a mixture. The mixture is subjected to a mixing method typically by passing it one or more times through one or more homogenizers or emulsifiers to form an emulsion of oil in water which the antigen confers. Any commercially available homogenizer or emulsifier can be used, for example Ross emulsifier (Hauppauge, NY), Gaulin homogenizer (Everett, MA) or Microfluidics (Newton, Ma). Alternatively, the various components of the adjuvant emulsion, including the oil, one or more surfactants and an aqueous component may be first combined to form a submicron emulsion of oil in water using a homogenizer or emulsifier; and the antigen is then added to this emulsion. The average particle size of the emulsion of oil in water after primary mixing is about 1.0-1.2 micrometers. The emulsion containing the animal is then subjected to microfluidization to bring the size of the drops to the submicron range. Microfluidization can be achieved using a commercial microfluidizer such as model number 110Y available from Microfluidics, Newton, Mass; the 30CD model of Gaulin (Gaulin, Inc., Everetf, Mass.); and Rainnie Minilab at 8.30 am (Miro Aomizer Food and Dairy Inc., Hudson, Wis.). The size of the goulash can be determined by a variety of methods known in the art, for example, laser diffraction, using commercially available measuring instruments. The size may vary depending on the type of surfactant used, the relationship between the surfactant and oil, the pressure at which it is worked, the temperature and the like. A desired combination of these parameters can be determined to obtain emulsions with a desired gage size. The oil content of the emulsions of the present invention is less than 1 μm in diameter. Preferably the average size of the goles is less than 1.8 μm. More preferably, the average droplet size is less than 1.5 μm. Even more preferably, the average droplet size is between 0.1 μm and 1.3 μm. In a preferred embodiment of the present invention, the DRAKEOL® lecithin oil solution, containing 25% lecithin in fluid paraffin oil, is combined and mixed with the surfactants TWEEN® 80 and SPAN® 80 and saline to form a mixture which contains 40% fluid paraffin oil, TWEEN® 80 at 0.18%) and SPAN® 80 at 0.08%. The mixture is then emulsified with a Ross® emulsifier (Hauppauge, NY 11788) at approximately 3400 rpm to form an emulsified product which is also referred to as "AMPHIGEN® formulation" or "AMPHIGEN® solution". Subsequently, the desired antigen (s) are combined with the AMPHIGEN® solution and any other suitable compounds (for example immunosfigurative molecules) with the aid of an emulsifier, for example, Ross homogenizer, to form a water emulsion in oil that contains the antigen (s). Such an emulsion is passed once through a Microfluidizer that works at 6895 ± 3447.5 pKa. The emulsion of oil in water has sizes less than 1 μm, with an average droplet size of approximately 1.25 μm. In another preferred modality, before combining an oil-in-water emulsion (for example an AMPHIGEN® formulation) with a desired antigen (s), the antigen (s) is combined with a saponin glycoside , for example Quil A, forming a mixture. This mixture of the enzyme (s) and saponin is subjected to homogenization, for example, in a homogenization vessel. Then a stellar, for example, cholesterol, is added to the homogenized mixture of antigen (s) and saponin. Then, the mixture that contains the anigen (s), saponin and stellar is again subjected to homogenization. Then, the mixture of antigen (s), saponin and homogenized spherical is combined with an emulsion of aceifene in water (for example an AMPHIGEN® formulation) with the aid of a homogenizer, for example. Then, the oil-in-water emulsion containing the amphiphile (s), saponin and stellar is subjected to homogenization at elevated pressure, as well as microfluidization. .
Compositions of Vaccines Containing Microencapsulated Anigenes in a Submicromerric Emulsion of Oil in Water and Preparation Methods Still in another embodiment, the present invention provides compositions of vaccines that contain a microparticle encapsulated anigen (or "microencapsulated agent"), those that the microencapsulated anigen is incorporated exlrinsically to a submicromeriric oil-in-water emulsion described above. Methods for absorbing or trapping antigens in particulate vehicles are well known in the art. See for example Pharmaceutical Particulate Carriers: Therapeutic Applications (Justin Hanes, Masaioshi Chiba and Robert Langer, Polymer microspheres for vaccine delivery, In: Vaccine design, The subunit and adjuvaní approach, Editors Michael F. Powell and Mark J. Newman, 1995 Plenum Press , New York and London). The particulate carriers can present multiple copies of a selected antigen to the immune system in an animal subject and promote the capylation and retention of amphigens in the local lymph nodes. The particles can be phagocytosed by macrophages and can potentiate the presentation of antigens through the release of cytokines. Particulate carriers have also been disclosed in the art and include, for example, those derived from polymethylacrylate polymers of methyl, as well as those derived from poly (lactides) and poly (lacyda-co-glycolides), which are known as PLG. Polymethyl methacrylate polymers are not biodegradable while PLG particles can be biodegradable by non-enzymatic random hydrolysis of ester linkages to lactic and glycolic acids that are excreted by normal metabolic pathways. Biodegradable microspheres have also been used to achieve controlled release of vaccines. For example, a sustained release of antigen can be achieved over a prolonged period. Depending on the molecular weight of the polymer and the ratio of lactic and glycolic acid in the polymer, a PLGA polymer can have a hydrolysis rate from a few days or weeks to several months or a year. A slow and controlled release can cause the formation of high levels of antibodies similar to those observed after multiple injections. Alternatively, a pulsatile release of antigens from the vaccines can be achieved by selecting polymers with different rates of hydrolysis. The rate of hydrolysis of a polymer typically depends on the molecular weight of the polymer and the ratio of lactic acid to glycolic acid in the polymer. Microparticles that are formed by two or more different polymers with variable rates of release of anligens provide pulsatile releases of antigens and mimic multiple-dose vaccination schedules. In accordance with the present invention, an antigen, including any of those described above, can be absorbed onto a particulate polymeric carrier, preferably a PLG polymer, using any method known in the art (such as that exemplified in the example). 17) to form a microencapsulated animal preparation. The microencapsulated antigen preparation is then mixed and dispersed in a submicron emulsion of oil in water, emulsion which has been described above, to form the vaccine composition. In a preferred embodiment, the present invention provides a vaccine composition containing an antigen encapsulated in a PLG polymer, in which the microencapsulated antigen is extrinsically dispersed in an oil emulsion in microfluidized water that is composed of paraffin oil. fluid, lecifin, TWEEN80, SPAN80 and saline solution and has an average droplet size of less than 1.0 μm.
Complexes formed by a saponin and a stellate In one embodiment, the present invention provides compositions containing a saponin and a esoteric, in which the saponin and the steral form complexes in the form of helical micelles. According to the present invention, these complexes have immunosimulatory activities. By "immunostimulatory" it is meant that the complexes can potentiate the immune response induced by an antigen component or that the complexes can induce an immune response independent of a separate antigen component. According to the present invention, a preferred saponin for use in a composition of the present invention is Quil A. Preferred spherals for use in the adjuvant compositions of the present invention include beía-siioslerol, esigmasterol, ergosterol, ergocalciferol and cholesterol. These esterales are notorious in the art, for example, cholesterol is described in Merck Index, 11th Edition, page 341, as a natural esteral found in animal fat. More preferably, the esteral is cholesterol. The ratio of saponin to stellar in the composition is typically from about 1: 100 to 5: 1 by weight. Preferably, the ratio is 1: 1.
In another embodiment, the present invention provides vaccine compositions containing a saponin, a sterol and an antigen, in which saponin and eserol form complexes in the form of helical micelles and in which the anigen is mixed but not incorporated into the helical micelles. The following are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only and are not intended to limit the scope of the present invention in any way.
EXAMPLE 1 Preparation of an AMPHIGEN® formulation
A formulation of AMPHIGEN® was prepared by a two-stage method. In the first stage 80 liters of Drakeol lecifin oil solution, 116 liters of Tinane Toxoid saline, 1.2 liters of SPAN 80, and 2.8 liters of Tween 80 were mixed and emulsified using a Ross emulsifier. The resulting solution in Drakeol lecithin oil contained 25% soy lecillin and 75% paraffin wax. The emulsified product was redrilled by the Ross emulsifier for a minimum of 5 volumes or a minimum of 10 minutes. The emulsified product was stored at 2-7 ° C for a maximum of 24 hours for further processing. The emulsion of the Ross emulsifier tank was transferred to a Gaulin homogenizer and homogenized for 20 minutes at a pressure of 3,102.75 kPa. The 40% drakeol lecithin oil solution (hereinafter "AMPHIGEN® formulation" or "AMPHIGEN® solution") was then dispensed in sterile polypropylene carboxy containers. The distribution was made within a class 100 distribution hood located in a controlled class 10,000 environment. The containers were stored at 2-7 ° C. This formulation of AMPHIGEN® was used in the experiments described below unless otherwise indicated.
EXAMPLE 2 Primary mixing by homogenization by ultrafast mixing of BVD vaccine
The apparatus used for this homogenization method is shown in Figure 1. Using aseptic technique or cross-vapor valves, a vial containing a BVD Type I antigen (an inactivated BVD Type I viral preparation) was attached to the port of the lower part of the mixing vessel. After completing the transfer of the required volume of the BVD Type I antigen, the BVD Type I bottle was replaced by the container containing a BVD Type II viral preparation (an inactivated BVD Type II viral preparation). After completing the transfer of the required density of a Type II BVD anigen, the Ross homogenizer was attached to the portable container and recirculation started at the maximum RPM (3300 rpm).
The agitation of the vessel was maintained at medium speed. Using aseptic technique or cross-vapor valves, a bottle containing Quil-A with a concentration of 50 mg / ml was attached to the in-line port of the homogenizer of the mixing vessel. A required amount of the Quil-A solution was passed to the vessel through in-line suction. After completing the transfer of Quil-A solution, the bottle was removed. In the same way, a required amount of cholesterol in eilanol solution (18 mg / ml) was transferred to the mixing vessel. Subsequently, a required amount of the AMPHIGEN® formulation, 10% thimerosol solution and dilution solutions of Eagle's Modified Basic ("BME") medium were added to the mixing vessel. Once the additions were completed, mixing continued for another 15 minutes. The resulting formulation was divided into 2 ml aliquots and represented a BVD vaccine with AMPHIGEN® formulation base not microfluidized. Each dose of the vaccine contained 500 μg of Quil-A, 500 μg of cholesterol, 2.5% AMPHIGEN® formulation and 0.009% thimerosol. The antigen concentration for the two different BVD strains was determined in terms of the ELISA assay for gp53.
EXAMPLE 3 Secondary mixing by microfluidization
Figure 2 illustrates the method used for secondary mixing mediating microfluidization. The microfluidizer was steam sterilized. First the camera of the auxiliary processing module was installed in the unit and the camera of the target was installed in the second position of the camera. The container conferring the BVD vaccine with all the adjuvants prepared as described in Example 2 was connected to the microfluidizer by attaching a transfer line from the drain valve of the supply container to the intake of the microfluidizer. Nitrogen gas was connected to the air intake of the supply vessel and the vessel pressure was adjusted to 137.9 +/- 34,475 kPa. The drain valve of the collecting vessel was connected to the transfer line of the microfluidizer outlet. After making all the necessary connections, the valves were opened and microfluidization was started with an opening pressure of 6895 +/- 3447.5 kPa. The entire contents of the vaccine were passed through the microfluidizer once and collected in the post-microfluidization chamber. This preparation was divided into 2 ml aliquots and represents the BVD vaccine with a microfluidized AMPHIGEN® formulation base.
EXAMPLE 4 Preparation of a vaccine composition by bank mixing
The AMPHIGEN® formulation prepared as described in Example 1 was diluted to 2.5% by adding BVD antigens and the diluent. The resulting solution was mixed on the bench using a stir bar instead of a homogenizer. The final preparation contained the following composition: BVD Type 1 and Type 2 antigens, 2.5% AMPHIGEN® formulation (which contains oil, lecithin, SPAN® and TWEEN®, as described in Example 1) and saline solution. . TWEEN 80 and SPAN 80 are present in the final vaccine preparation at 0.18% and 0.08% or in volume respectively.
EXAMPLE 5 Comparison of the droplet size distribution between preparations of the non-microfluidized and microfluidized AMPHIGEN® formulation based vaccines
The non-microfluidized AMPHIGEN® formulation-based vaccine prepared as described in example 2, the microfluidized AMPHIGEN® formulation-based vaccine prepared as described in Example 3 and the preparation prepared by bench-mix as described in Example 3. described in Example 4 were used to compare the size of the drops of the vaccine preparations. 2 ml of the sample from each of the preparations was added to a Malvern 2000 laser diffractometer and the size distribution of the lozenges was determined. As shown in Figure 3, the results indicate that the microfluidifi- cated AMPHIGEN® formulation-based vaccine preparation had the maximum particle volume around 0.1 micrometers while the non-microfluidifi- cated AMPHIGEN® formulation-based vaccine preparation had the maximum volume of particle distribution around 1 micron.
EXAMPLE 6 Reduction of phase separation of vaccines.
Fresh preparations of the different vaccines were compared: the non-microfluidized AMPHIGEN® formulation-based vaccine prepared as described in example 2, the microfluidized AMPHIGEN®-based formulation vaccine prepared as described in example 3 and the vaccine prepared by bank mixing as described in example 4, to determine its phase separation properties after prolonged storage. All these preparations were allowed to stand at 4 ° C for about a month and the phase separation was carried out considering the appearance of a creamy layer in the upper part of the vaccine preparations. As shown in FIG. 4, no phase separation occurred in the microfluidized AMPHIGEN® formulation-based preparation when compared to the other two preparations.
EXAMPLE 7 Preparation of vaccine for microfluidized and non-microfluidized bovine cattle against bovine viral diarrhea virus
Viral antigen of bovine diarrhea virus was incorporated into the AMPHIGEN® formulation by microfluidization. The term "intrinsically incorporated" refers to the method by which the antigen was added to the AMPHIGEN® formulation prior to microfluidization. The antigen was subjected to the physical forces of the microfluidization method together with the components of the adjuvant formulation. In the non-microfluidized control group, the antigen preparation was dispersed in the AMPHIGEN® formulation by mixing. The final composition of the control and microfluidized preparations was as follows: BVD type I with an ELISA titration after inactivation of 2535 UR / dose for gp53, BVD Type II with an ELISA titration at inactivation of 3290 UR / dose for gp53 , Quil-A with a concentration of 1.25 mg / dose, cholesterol with a concentration of 1.25 mg / dose, the formulation of AMPHIGEN® with a final concentration of 2.5% and thimerosol with a final concentration of 0.009%). The dose of the vaccine was 5 ml.
EXAMPLE 8 Long-Term Stability of BVD Viral Antigens Incorporated in an Intrinsic Way to the Preparation of Microfluidifiated AMPHIGEN® Formulation-Based Vaccine
This experiment was performed to determine the stability of the antigen incorporated intrinsically during long-term storage. The BVD Type II viral antigen was incorporated in an inírinseca form
Activated to the formulation of AMPHIGEN® during the microfluidization method to obtain a microfluidized vaccine preparation
(A907505). Three other preparations of the vaccines containing the same antigen in a non-microfluidized AMPHIGEN® formulation (A904369,
A904370 and A904371) served as conirols. In the non-microfluidized preparations, the antigen was mixed with the AMPHIGEN® formulation and mixed by beating with a Ross homogenizer. The four preparations of the vaccines were stored at 4 ° C for two years. At different times during storage (0, 6, 12 or 24 months), the formulations were used to vaccinate months-old cows. On days 0 and 21 three month old cows were vaccinated subcutaneously with a 2 ml vaccine formulation. The serum of the vaccinated animals was extracted on day 35 and the serological response to the vaccine was measured by titrating the antibodies by means of a BVDV-E2 ELISA. As shown in Figure 5, the microfluidized vaccine preparation showed a higher antibody titration at all analyzed times (0, 6, 12 and 24 months), which suggests that the stability of the antigen preparation was not loses during the intrinsic incorporation of the antigen during the microfluidization method. In addition, it was also surprisingly found that the preparation of microfluidized vaccine induced an enhanced immune response at all times.
EXAMPLE 9 Reduction in rectal temperature increase induced by the vaccine after microfluidization
The preparations of the microfluidized and non-microfluidized vaccines were used as described in example 7 to vaccinate the cattle on day zero and the rectal temperature was monitored during the period from one day before the vaccination until four days after the vaccination. The dose of the vaccine was 2 ml. The groups were vaccinated with a single or double dose of the vaccine. Rectal temperatures were measured and recorded daily from Day 1 to Day 4 inclusive. Rectal temperatures were measured on day 0 before administration of the experimental article.
As shown in Figure 6, the results indicate that there was a sharp increase in rectal temperature approximately 24 hours after vaccination in animals vaccinated with a single or double dose of the non-microfluidized vaccine formulation. However, in the animals vaccinated with microfluidized forms of the vaccine, the increase in the temperature after vaccination was minimal and significantly lower than in the animals vaccinated with the non-microfluidized formulation (Figure 6).
EXAMPLE 10 The reaction volume in the injection site resolved faster when it was vaccinated with formulations of the microfluidized vaccines
preparations of the vaccines used microfluidifizadas not microfluídifizadas prepared as described in Example 7 to immunize cattle on day zero. The animals included in this study were hybrid beef cattle. There were three animals in each of the placebo treatment groups (T01 and T02). There were six animals in each of groups T03 to T06. The vaccine dose was 2 ml and the groups were vaccinated with one or two doses of the vaccine on day zero. On day 0, the test article was administered on the right side of the neck. The animals that received the double dose (4 ml) of the experimental article (T02, T03 and T06) received the full double dose in the form of a single injection on one side. The observation of the injection zones, including the estimation of the reaction zone in the area of the injection was made on the right side of the neck from Day 0 to Day 4 inclusive, and Days 6, 9 and 14. The Day 0 the injection zones were observed before the administration of the experimental articles. Groups vaccinated with one or two doses of placebo showed no significant increase in reaction volume in the injection site and therefore these data are not shown in Figure 7. In the case of non-microfluidized vaccine formulation, produced a proportional increase in the volume of reaction in the area of the injection between vaccination with one dose and with two doses. On the other hand, in the case of the microfluidized vaccine formulation, although the single dose induced a larger reaction volume in the area of the injection, the injection with the second dose did not cause an additional increase. However, in the case of the animals injected with the microfluidized vaccine formulation, the reaction volume in the injection site was resolved with a higher velocity compared to that of the animals injected with a vaccine. formulation of non-microfluidized vaccine. These results are shown in figure 7.
EXAMPLE 11 Preparation of a Microfluidifi- cated AMPHIGEN® Formulation-Based Vaccine. Preparations with intrinsically incorporated BVD and Leptospira viral antigens and immunostimulatory molecules such as Quil A and DDA
Leptospira hardjo-bovis of the CSL strain inactivated in formalin was formulated with the appropriate adjuvant with direct counts of approximately 1.4 x 109 organisms / 5 ml dose. The Lepiospira Pomona T262 strain born in formalin was formulated at approximately 2400 nephromeric units / 5 ml dose. Nephalomeric units were calculated based on the nephrometric measurement of previously processed fermentation fluid. Type 1 BVD virus was formulated with an E2 Elisa titre of approximately 3000 relative units / 5 ml dose. Type 2 BVD virus was formulated with an E2 ELISA titration of approximately 3500 relafive units / 5 ml dose. The relative unit was calculated based on the evaluation in E2 ELISA of bulk fluid after inactivation before assembly. Quil-A tannery was used as colesterol with a concentration of 1.5 mg per dose. Thimerosol and the AMPHIGEN® formulation were used with final concentrations of 0.009% and 2.5% respectively. Aluminum hydroxide (Rehydragel LV) with a final concentration of 2.0% was used. When DDA was used as an immunomodulator, DDA was included in the AMPHIGEN® formulation. The AMPHIGEN® formulation (ie, the 40% Drakeol-lecithin stock solution) contained 1.6 mg / ml DDA and, when properly diluted, the final vaccine preparation contained 2.5% AMPHIGEN® formulation and 0.1 mg / ml of DDA. Fractions of BVD, Leptos, Quil-A, cholesterol, thimerosol were added in the preparation of different formulations of the vaccines., the formulation of AMPHIGEN® and saline as diluent to a Silverson homogenizer and mixed for 15 minutes at 10,000 + 500 rpm. The components were then microfluidised with a 200 micron sieve at 68,950 kPa. When the vaccine formulation contained aluminum hydroxide, the microfluidization was carried out without aluminum hydroxide. When the microfluidization was completed, aluminum hydroxide was added and mixed with a stir bar until the next morning at 4 ° C.
EXAMPLE 12 Preparation of BVD virus vaccine for exposure studies
The vaccine preparation used in this experiment congested BVD Type 1 virus amphe- lenes and BVD Type 2 virus. BVD1-5960 antigen was used with an ELISA titration of 2535 UR / dose for gp53. The BVD2-890 antigen was used with a post-inactivation ELISA titre of 3290 UR / dose for gp53. Quil-A and cholesferol were used at a concentration of 1.5 mg / ml. Iimersol and the AMPHIGEN® formulation were used with a final concentration of 0.009% and 2.5% respectively. When DDA was used as an immunomodulator, DDA was included in the AMPHIGEN® formulation. The stock solution of AMPHIGEN® (40% Drakeol-lecifin solution >) contained varying amounts of DDA and, when properly diluted, the final vaccine preparation contained 2.5% AMPHIGEN® formulation and a DDA concentration which varied in the range of 1.5 mg / dose to 2.0 mg / dose. Aluminum gel (Rehydragel-LV) with a final concentration of 2% was used. GPI-0100 was used in the range of 2, 3 and 5 mg / dose. All components were added to a homogenizer
Silverson and were mixed for 15 minutes at 10,500 rpm and then microfiluted by passing them through a 200 micrometer chamber at 68,950 kPa. When the vaccine formulation contained aluminum hydroxide, the microfluidization was carried out without aluminum hydroxide. When the microfluidization was completed, aluminum hydroxide was added and mixed with a stir bar until the next morning at 4 ° C.
EXAMPLE 13 Protection against exposure to Leptospira after vaccination with a microfluidized formulation of Amphigen vaccine with Leptospira antigens
TABLE 1 Treatment groups
Table 1 shows the composition of the adjuvant formulations of the vaccine preparations that are experienced in this study. The preparations of the vaccines were prepared as described in example 11. There were six animals in each group. In this study, hybrid beef steers of approximately seven months of age were used. Vaccination was carried out on Day 0 and Day 21 subcutaneously with a volume of 5 ml vaccine. The exhibition was carried out with L. hardjo-bovis strain 203 of the NADC (National Agricultural Disease Center). The exposure was carried out during days 57-59 with an inoculum of 1 ml. The exposure was administered via the ocular conjunctiva and vaginally. The exposure material contained 5.0 x 106 leprospiros / ml. The urine was collected weekly to perform a culture of leptospira, FA and PCR. The kidneys were removed during Days 112 and 113.
TABLE 2 Results of the Leptospira exposure study
Table 2 shows the data from the exposure study
Leptospira. To determine the percentage of Leptospira infection in the exposed animal, the following criteria were used. If the kidney culture was positive in only one sample, the animal is considered positive for Leptospira. If an animal is positive only in a sample for FA or PCR, the animal is considered negative. If the sample is positive for FA and PCR in only one sample, it is considered positive for Leptospira. The results shown in table 2 indicate that the duration of presence in urine in all vaccinated groups was significantly shorter based on the fres trials. In regard to urinary and renal colonization, the efficiencies of the formulations containing QAC and DDA without AIOH were comparable. The AIOH did not improve or even reduce the efficacy of the vaccines containing QAC or DDA in this exposure study.
TABLE 3 Evaluation interval of microscopic agglutination on the day of assessment with maximum geometric mean before exposure (Day 35)
Serological responses were detected against both Leptospira antigens of the vaccine formulation in the vaccinated animals and the maximum response was observed on Day 35. There was no correlation between the serological response and the protection against exposure. The presence of aluminum gel in the vaccine formulation reduced the level of protection although the serological response was enhanced by the presence of aluminum gel in the vaccine.
EXAMPLE 14 Provocation of immune response to BVD viral antigen and
Protection against BVD Type 2 virus exposure after immunization with a microfluidized vaccine preparation containing AMPHIGEN® and DDA formulation
In this experiment, seronegative calves from four to seven months of age were used. There were six different groups and each group had ten animals (table 4). On Day 0 and Day 21 each animal received a subcutaneous dose of 2 ml of the vaccine or placebo on the lateral neck approximately midway between the scapula and the head.
TABLE 4 Treatment groups
of the virus (approximately 2.5 ml per tose) intranasally on day 44 of the study. In this study BVD type 2 virus was used, isolated strain n ° 24515 (Ellis strain), batch no. 46325-70 non-cytopathic as the exposure strain. The retained samples of exposure material (two repetitions per assessment) were assessed at the time of the start of the exposure and immediately after completion. The average live virus titration per 5 ml dose was 5.3 log-io FAID50 / 5 ml before exposure and 5.4 log10 IDAD5o / 5 ml at exposure (FAID is equivalent to TCID50). Animals were convalesced every day from Day 3 to day 58. Clinical disease scores of 0, 1, 2, or 3 were assigned based on clinical signs attributable to BVD 2 infection for each animal on Days 42 to 58. Day 44 scores were recorded before the exhibition. Blood samples (two 13 ml serum separation tubes, SST) from each animal were taken on Days 0, 21, 35, 44 and 58 to determine serum titers of BVD Type 1 and BVD virus neutralization antibodies. Item 2. Blood samples were taken from each animal from Day 42 to Day 58 inclusive, and the presence of BVD virus in the buffy coat was determined. On Day 44, samples were taken before the exhibition. Blood samples (a 4 ml EDTA tube) were taken to determine leukocytometry from Day 42 to Day 58 inclusive. On Day 44 samples were obtained before exposure. Leukopenia was defined as a 40% or greater decrease in leukocilomelry compared to the initial level (leukocytometry prior to the mean exposure of two days before and on the day of exposure). Clinical disease punctuations were used to define the disease state as follows; if the puniuation is < 1, then disease = no; if the puniuation is > 2, then disease = yes. As shown in Tables 5 and 6, the groups that were vaccinated with vaccines containing BVD June viral antigens with the formulation of AMPHIGEN®, Quil A or DDA and microfluidized, were seroconverted with significant serum virus neuralization titers. for BVD Type 1 and BVD Type 2 viruses. In those groups there was also a significant reduction in the percentage of animals showing viraemia after exposure, while in the control group 100% of the animals showed viremia (Table 7) . In addition, in the vaccinated groups the frequency of the disease was also significantly reduced (Table 8). Similarly, the percentage of animals showing leucopenia was also reduced in the vaccinated groups and the reduction in leukopenia was more significant in the group containing DDA than in the group containing Quil A (Table 9). In the control group there was a significant decrease in the weight gain compared with the vaccinated groups (Table 10).
Serology Prior to vaccination on Day 0, all the animals in the study were seronegative (SVN <1: 2) for antibodies to BVD Virus Types 1 and 2 (data not shown). Fourteen days after the second vaccination (Day 35) all the animals given placebo (T01) were still seronegative for antibodies against the BVD virus Types 1 and 2; and all the animals vaccinated with the ITA (Anígen in research experimentation) (T02, T03, T04, T05 and T06) were seropositive (SVN >; 1: 8) for antibodies against the BVD virus, Types 1 and 2. An animal that was administered the adjuvanted vaccine of the AMPHIGEN® formulation at 2 mg / dose of DDA had an SVN rating of 3 for antibodies against BVD Type 2 virus on Day 35 (Table 11 and 12). Prior to exposure on Day 44, all controls (T01) except one, were seronegative (SVN < 1.2) for antibodies against BVD viruses Types 1 and 2 (data not shown). One of the controls (n ° 2497) was seropositive (SVN = 10) for antibodies against the BVD Type 1 virus and seronegative for the BVD Type 2 virus. Fourteen days after exposure, all the animals in the study were seropositive for antibodies against the viruses. BVD virus Types 1 and 2.
TABLE 5 Geometric mean of serum virus neutralization titers for BVD Type 1 virus
TABLE 6 Geometric mean of serum virus neutralization titers for BVD Type 2 virus
TABLE 7 Isolation of BVD virus after exposure
TABLE 8 Clinical signs of BVD disease after exposure
TABLE 9 Leukopenia after exposure TABLE 10
Virus Isolation As shown in the data in Table 13, during the exposure period (Days 44 to 58), the ten animals of the control group (T01) suffered viremia (the BVD virus was isolated one or more days). In the groups to which the ITAs had been administered, the frequency of animals with viremia was one, zero, fres, two and two in each group of ten (T02, T03, T04, T05 and T06, respectively). The difference between the groups of conírol and the groups to which the ITAs had been administered was statistically significant (P <0.05). The mean of the least squares of the number of days of viremia was also significantly higher (11.4 days) for the control compared with the groups to which the ITAs had been administered (0.0 to 1.5 days).
Clinical Disease It was considered that animals with clinical signal scores of 2 or 3 showed signs of BVD disease. As shown in Table 14, the frequency of animals with clinical signs of BVD virus disease was nine out of ten in the control (T01) and one, two, zero and zero out of ten in each of the groups at that they were administered the ITA (T02, T03, T04, T05 and T06 respectively). The difference between the control and the groups to which the ITAs were administered was statistically significant (P <0.05).
Leukopenia As shown in Table 15, during the exposure period (Days 44 to 58), the ten control animals (T01) suffered from leukemia (a reduction of 40% or in leukocytry compared with the initial before exposure). , Days 42-44). The frequency of animals with leukemia was six, two, four, fres and two of the ten animals of each of the groups to which the ITAs were administered (T02, T03, T04, T05 and T06 respectively). The difference between the confrol and the groups to which the vaccine containing the formulation of AMPHIGEN® was administered as an adjuvant at 1.5 mg / dose and aluminum hydroxide (T03) was statistically significant (P <0.05). The mean of the least squares of the number of days of leukemia was significantly higher (7.8 days) for the control compared with the groups to which the ITAs were administered (1.2 to 1.2 days).
EXAMPLE 15 Provocation of immune response to BVD viral antigen and protection against BVD type 2 virus challenge after immunization with a microfluidized vaccine preparation containing GPI-0100
A group of experimental conditions such as the one described in Example 14 was followed and a direct comparison was made between Quil A and GPI-0100. As shown in Tables 11 and 12, animals vaccinated with BVD antigens in the microfluidifi- cated AMPHIGEN® formulation preparation that contained Quil-A or GPI-0100 had a significant antibody titre for BVD Type 1 and BVD viruses. Type 2. The antibody titre for the BVD Type 1 virus was much higher than that of the BVD Type 2 virus. However, the subsequent exposure to BVD Type 2 virus demonstrated a potent protection and significantly reduced the incidence of the disease in the BVD Type 2 viruses. calves vaccinated with the vaccine preparation based on AMPHIGEN® microfluidized formulation containing GPI-0100.
TABLE 11 Geometric mean of serum virus neutralization titers for BVD virus type 1
TABLE 12 Geometric mean of serum virus neutralization titers for BVD Type 2 virus
TABLE 13 Isolation of BVD virus after exposure
TABLE 14 Clinical signs of BVD disease after exposure
Treatment Frequency Frequency (%) observations with Total (%) with a disease score Obs. Clinical disease of 0 1 2 T01 Saline solution 5/10 (50.0) 103 (60.6) 55 (32.4) 12 (7.1) 170 T02 Amphigen. 5/10 (50.0) 115 (67.6) 48 (28.2) 7 (4.1) 170 Quil A T03 Amphigen. 0/10 (0.0) 128 (75.3) 42 (24.7) 0 (0) 170 2 mg of GPI-0100. AIOH T04 Amphigen. 0/10 (0.0) 124 (72.9) 46 (27.1) 0 (0) 170 2 mg of GPI-0100 T05 Amphigen. 0/10 (0.0) 104 (61.2) 66 (38.8) 0 (0) 170 3 mg of GPI-0100 T06 Amphigen. 0/10 (0.0) 128 (75.3) 42 (24.7) 0 (0) 170 5 mg of GPI-0100
TABLE 15 Leukopenia after exposure
In conclusion, the safety of each vaccine was demonstrated by the
absence of adverse death reactions in vaccinated animals.
The potency of each vaccine was demonstrated by seroconversion (titers of SVN antibodies for BVD-1 and BVD-2> 1: 8) in 100% of the vaccinated animals. The vaccine with 2 mg of GPI-0100 only as adjuvant showed satisfactory resistance to exposure.
EXAMPLE 16 Preparation of vaccine containing microencapsulated antigen in water-in-water microfluidized emulsion
Three grams of Trehalose (Fluka) were added to water to obtain a stock solution of 333 mg / ml Trehalose solution. Recombinant PauA antigen solubilized in 1.8% SDS solution was added
(SDS / rPauA) to the Trehalose solution to obtain a final concentration of 494 μg rPauA / ml. In the next step, 10 grams of polylactidaglucolic acid (PLG-Resomer RE 503H, Boeringher Ingelheim) was dissolved in 200 ml of methylene chloride (MeCl2). The resulting solution of PLG / MeCI2 was combined with the SDS-rPauA / trehalose solution prepared in the first step. The combined solution was subjected to microfluidization using
Microfluidizer (from Microfluidics Model M110EH) and microfluidized preparation was spray dried using Temco Spray Dryer (Model SD-5). The spray dried material was collected using a 500 micron sieve. The concentration of rPauA in this spray-dried material was quantified using a Western blot analysis. 1.04 mg of spray-dried material was dissolved in 50 μl of acetone and centrifuged at 13,200 rpm at ambient temperature for 10 minutes. The supernatant was eliminated. The supernatant and sediment fractions were dried in a biological safety hood for 2.5 hours. The pellet was resuspended in 47.43 μl of sample solution (25 μl of sample pH regulator + 10 μl of reducing agent + 65 μl of water). The dried supernatant fraction was resuspended with 20 μl of sample solution. In the Western analysis, purified PauA was used as a payroll to quantify the rPauA content of the spray dried material. A stock solution of 20% manifold or dissolving was prepared
100 grams of maniol (Sigma) in 500 ml of water for injection (WFI). The solution was heated to 40 ° C with heating plate / agilator and cooled to 30 ° C. The solution was sterilized by filtration with a sterile 1.22 micromembrane filter (Millipore). A 2.5% carboxymethylcellulose solution was prepared) by dissolving 12.5 grams of carboxymethylcellulose (Sigma) in 500 ml of WFI and mixed overnight at 4 ° C. The solution was sterilized in an autoclave at 121 ° C. The powder resulting from the spray drying was reconsiluted in a solution containing 5% mannol or, 1.3% carboxymethyl cellulose) and 1: 5000 imimerosol. The final solution was grown in vials in 3 ml aliquots and lyophilized using a Lyophilizer (USIFROID). The lyophilized powder represents the microencapsulated rPauA. The microencapsulated protein subunit antigen was resuspended in 2 ml of microfluidized water-in-water emulsion containing an AMPHIGEN® formulation (as the microfluidized emulsion described in Example 20) and used as a vaccine.
EXAMPLE 17 Preparation of a microfluidized vaccine formulation containing both whole cell bacterial antigen and recombinant protein antigen in oil in water emulsion
Two preparations of the PauA recombinant Streptococcus uberis-containing vaccines were prepared as bacterial cells of Escherichia coli, intrinsically added to oil-in-water emulsions as described in examples 2 and 3. The recombinant PauA anigen was at a concentration of 100 μg per dose and the E. coli cells gave a final count of 4 x 109 per dose. The compositions of the emulsion adjuvants of the two formulations of the vaccines are shown in Table 16.
TABLE 16 Formulations of vaccines containing both recombinant protein and whole cells of E. coli
EXAMPLE 18 Immune response to the microfluidized vaccine containing the oil in water emulsion with rPauA and whole cell bacterial agents
In this experiment, mature dairy cows were used. The animals were at the end of their first or second lactation at the time of admission. Two ml of each vaccine formulation were administered subcutaneously one fold times, one at the time of drying (D-0), 28 days later (D = 28) and again 4 to 10 days after delivery (C + 4 - C + 10). The first and third doses were administered on the left side of the neck and the second dose was administered on the right side of the neck. Blood was drawn before each vaccination and approximately 14 days and 32 days after the first vaccination.
Antibody titers against E. coli and the rPauA antigen were determined by ELISA. As shown in Figure 8, the results indicate that the assessment of antibodies to rPauA was higher in the group vaccinated with the vaccine formulation containing GPI-0100 as immunostimulant and was maximum on day 70 after the initial vaccination. The titration of antibodies to the antigen against E. coli is shown in Figure 9. The titration of antibodies against E. coli antigen was comparable in both formulations of the vaccines, although the presence of GPI-0100 as immunoscleragen induced an assessment of Relatively greater antibodies compared to the formulation with DDA as immunosimulant.
EXAMPLE 19 Analysis of virucidal activity of the preparations of the vaccines based on the formulation of AMPHIGEN® microfluidized
To determine if microfluidization inactivates the virus, the viricidal activity of fresh preparations of the microfluidifi- cated AMPHIGEN® formulation-based vaccines was determined. The preparations involved different infectious bovine virus, specifically bovine herpesvirus (BHV), parainfluenza virus 3 (PI3) and bovine respiratory syncytial virus (BRSV). The detection of the virucidal activity of the three preparations of the vaccines was carried out in accordance with the requirements of the USDA regulation 9CFR-113.35. The results shown in Table 17 indicate that the microfluidization of AMPHIGEN® formulation-based vaccine preparations does not cause significant degradation of the vaccine preparation.
TABLE 16 Analysis of virucidal activities of microfluidized vaccines
A = cholesterol added at 650 ml / minute B = cholesterol added at 28 ml / minute C = cholesterol added at 5 ml / minute M200 = microfluidized with 200 micron sieve M75 = microfluidized with 75 micron sieve M75 at 37C = heated fluids at 37 ° C before microfluidization A value above 1.7 indicates a virucidal effect.
EXAMPLE 20 Preparation of a microfluidized AMPHIGEN® formulation
An AMPHIGEN® formulation was prepared by combining lecithin oil solution DRAKEOL (fluid paraffin oil with 25% lecithin) and TWEEN 80 (with a final concentration of 0.18%) and Span 80 (with a final concentration of 0.08% > ) mixing for 8-22 hours at 36 + 1 ° C. The oil mixture was then added to saline with the aid of a Ross® emulsifier (Hauppage, NY 11788) at approximately 3400 rpm. Subsequently the mixture was passed once through a microfluidizer with an interaction chamber at 31,027.5 kPa ± 3.447.5 kPa. Figures 10A and 10B show the stability of the microfluidized AMPHIGEN® formulation. The size distribution of the particles, measured by laser diffraction, at the start (FIG. 10A) was almost identical to the particle size distribution after 22 months of storage at 4 ° C (FIG. 10b).
EXAMPLE 21 Analysis by electron microscopy of the immunogenic complex of Quil A and cholesterol
To determine the nature of the immunogenic complex formed by Quil A and cholesterol, a mixture of these two components was prepared either in the presence or in the absence of an antigen. In a flask containing 50 ml of HR-Hals pH regulator, BVD Type I antigen was added while stirring the solution with a magnetic bar. Then, a concentrated stock solution of Quil A (50 mg / ml) was added drop by drop while stirring the solution to a final concentration of 50 μg / ml. The addition of Quil A was followed with the addition of a stock solution of cholesterol in ethanol (18 mg / ml) to a final concentration of 50 μg / ml. In a second flask, Quil A and cholesterol were added in the same way to the 50 ml pH regulator without BVD Type I ampigen. For electron transmission microscopy, 10 μl of each sample was adsorbed onto 400 mesh copper gratings with a formvar and carbon support platform (Elecíron Microscopy Sciences, Inc., Fort Washington, PA). The samples were negatively stained using 10 μl of filtered 2% phosphotungsic acid, at pH 5.2 as a conirase agent. The samples were examined using a JEOL 1230 electronic transmission microscope (JEOL Inc., Tokyo, Japan) with an acceleration voltage of 80 kV.
Digital imaging was performed with a Gafan BioScan 792 camera. Film microscopy was performed on 4489 EM film and printed on Kodabrome II RC F3 paper (Eastman Kodak Company, Rochester, NY.). In the solution containing only cholesterol and Quil A without BVD Type I antigen, helical micelles were detected together with Quil A micelles and cholesterol crystals (Figure 11). The helical micelles were cross-linked and had a mesh appearance. In the sample containing the BVD Type I antigen, it was observed that helical micelles randomly surrounded certain dense areas (Figure 12). The dense areas represent the BVD Type 1 antigen and the helical immunogenic complex that is produced by the association of Quil A and cholesterol is adsorbed on the surface of the BVD Type I antigen. Having described the invention as above, it is declared as property content in the following:
Claims (8)
1. - A vaccine comprising a saponin glycoside, a stellar and an animal, wherein said saponin glycoside and said esoteric are associated with each other to form complexes in the form of helical micelles and in which said antigen is mixed, but not innate , in said helical micelles.
2. The vaccine composition according to claim 1, further characterized in that it also comprises a veterinarily acceptable vehicle.
3. The vaccine composition according to claim 2, further characterized in that said verieterly acceptable vehicle is an oil in water emulsion.
4. The vaccine composition according to claim 1, further characterized in that said saponin glycoside is an iodidenoid.
5. The vaccine composition according to claim 4, further characterized in that said triterpenoid is Quil A.
6. The vaccine composition according to claim 1, further characterized in that said steral is cholesterol.
7. The vaccine composition according to claim 1, further characterized in that said antigen comprises a viral agent, a bacterial agent or a combination thereof.
8. The vaccine composition according to claim 7, further characterized in that said antigen comprises a type 1 or type 2 BVDV antigen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/559,677 | 2004-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06011569A true MXPA06011569A (en) | 2007-04-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005230708B2 (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
US8771727B2 (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
IE903161A1 (en) | Adjuvant complexes | |
MXPA06011569A (en) | Microfluidized oil-in-water emulsions and vaccine compositions |